Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Parathyroid has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Parathyroid hormone is the main stimulus for the kidney enzyme that converts 25-hydroxyvitamin D into the active 1,25-dihydroxy form. The active hormone then raises calcium absorption from the gut and feeds back to suppress PTH release. The two sit in a closed loop, which is why PTH is measured whenever vitamin D status is being assessed.
The calcium-sensing receptor on the parathyroid cell reads ionised calcium in the blood minute to minute. A fall releases PTH within seconds, a rise shuts it off. Calcium intake therefore sets the tone of the whole axis, and a low-calcium diet produces a chronically raised PTH even when vitamin D is adequate.
Severe magnesium depletion blocks PTH release from the gland and blunts the response of bone and kidney to circulating hormone. The result is a low calcium that does not correct until magnesium is replaced, which catches people out because calcium supplementation alone fails. Mild magnesium shortfall does not do this.
Rising serum phosphate stimulates PTH release both directly and by lowering ionised calcium and suppressing active vitamin D. PTH in turn increases renal phosphate excretion, which is the corrective arm of the loop. High phosphate intake, common with processed food and cola, pushes the axis in the direction of higher PTH.
Active vitamin D drives osteoblasts to make osteocalcin, but the protein only binds calcium into the bone matrix once vitamin K dependent carboxylase has modified its glutamate residues. Without adequate vitamin K a portion of circulating osteocalcin stays undercarboxylated. The link to bone density outcomes in people is less settled than the biochemistry.
Boron supplementation has been reported to slow the breakdown of vitamin D metabolites and shift calcium and magnesium handling in small studies. The mechanism is not well characterised and the human work is limited in size. Read it as a signal worth noting rather than an established relationship.
Potassium citrate supplementation shifted bone turnover markers in postmenopausal women, with the proposed mechanism being reduced acid load and lower urinary calcium loss. Bone turnover markers are markers, not fracture outcomes. The direction is favourable but the endpoint is a surrogate.
Routine versus selective calcium supplementation after total thyroidectomy was compared in a randomised trial, because handling of the gland during surgery can transiently disturb calcium regulation. This is a clinical management question handled by a surgical team, not a self-directed supplement decision.
A systematic review of vitamin D2 found consistent effects on parathyroid hormone, calcium and phosphorus in humans. Both D2 and D3 raise 25-hydroxyvitamin D and suppress PTH, though they differ in potency and half-life. The suppression of PTH is the expected physiological response, not a separate benefit.
Nothing specific on file for Parathyroid. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.These are the studies our verdict leans on, chosen from the 8 we read for Parathyroid. The full linked list is below.
12 sources behind our Parathyroid verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
Read this carefully. These are 11,222 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Parathyroid is, not how risky it is. A report is not proof Parathyroid caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.